Jul 2 |
Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds
|
Jul 1 |
Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds
|
Jun 27 |
Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit
|
Jun 1 |
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
|
May 21 |
Purple Biotech GAAP EPADS of -$0.14 beats by $0.05
|
May 21 |
Purple Biotech Reports First Quarter 2024 Financial Results
|
Apr 25 |
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
|
Mar 28 |
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
|
Mar 14 |
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
|
Mar 5 |
Purple Biotech GAAP EPADS of -$0.19
|